salmeterol/fluticasone easyhaler / Orion Corp - LARVOL DELTA

Effectiveness and Treatment Compliance of Salmeterol-Fluticasone Easyhaler Among Patients with Asthma, COPD, or Asthma-COPD Overlap Syndrome: Real-World Study Findings. (PubMed, Pulm Ther) - "Treatment with SF EH significantly improved patients' lung function parameters and disease control."

Journal • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice. (PubMed, J Asthma) - "In general, patients show good compliance with medical product and are satisfied with the use of this new device, and not reporting difficulties and errors related to its' use. Their physicians' overall perception of Salflumix Easyhaler use is very positive."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler in routine clinical practice. (PubMed, Ther Adv Respir Dis) - "The results from this prospective real-life clinical study indicate better or at least similar treatment control of asthma and COPD after switching to S/F Easyhaler from another S/F inhaler. This study also shows that S/F Easyhaler was favored by the patients and that it is easy to teach, learn and use in a real-life setting.The reviews of this paper are available via the supplemental material section."

Clinical • Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

[VIRTUAL] LIFE CYCLE ASSESSMENT AND CRADLE-TO-GRAVE CARBON FOOTPRINT OF A MULTIDOSE RESERVOIR DRY POWDER INHALER (BTS WM 2021) - "GSK’s Carbon Trust-verified analysis including Relvar and Seretide Accuhaler is about 1 kg CO2e/inhaler, and Product Carbon Footprint analysis of Spiriva Respimat 0.780 kg CO2e...We conducted a Cradle-to-Grave (CTG) CO2FP analysis and LCA of four different Easyhaler® (EH) products available for the treatment of asthma and COPD (budesonide-formoterol; salmeterol-fluticasone; salbutamol, and formoterol EH)...Patients with asthma or COPD, and treating physicians alike, are increasingly aware of climate change and this affects even their treatment choices. When considering the climate impact of inhalation therapy, DPIs, like EH, have a minimal carbon footprint compared with MDI."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

SUNNY: Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD (clinicaltrials.gov) - P=N/A; N=231; Completed; Sponsor: Orion Corporation, Orion Pharma; Active, not recruiting ➔ Completed

Clinical • Trial completion

SUNNY: Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD (clinicaltrials.gov) - P=N/A; N=231; Active, not recruiting; Sponsor: Orion Corporation, Orion Pharma; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

SUNNY: Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD (clinicaltrials.gov) - P=N/A; N=310; Recruiting; Sponsor: Orion Corporation, Orion Pharma; Trial completion date: Nov 2019 ➔ Feb 2020; Trial primary completion date: Nov 2019 ➔ Feb 2020

Clinical • Trial completion date • Trial primary completion date

SUNNY: Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD (clinicaltrials.gov) - P=N/A; N=310; Recruiting; Sponsor: Orion Corporation, Orion Pharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open